Data / Form D filings / X4 Pharmaceuticals, Inc
X4 Pharmaceuticals, Inc: Form D filings
X4 Pharmaceuticals, Inc, a biotechnology company in Boston, MA, filed 12 Form D notices with the SEC between 2010 and 2025. The latest, on August 25, 2025, reports $85 million sold of a $85 million offering to 18 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 61 NORTH BEACON STREET, 4TH FLOOR, Boston, MA, 02134
- Phone
- (857) 529-8300
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1501697
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 25, 2025 | New notice | $84,999,985 | $84,999,985 | 18 | Aug 13, 2025 | sec.gov | |
| Jun 1, 2023 | New notice | $65,023,725 | $65,015,462 | $8,263 | 22 | May 18, 2023 | sec.gov |
| Jul 19, 2022 | New notice | $111,526,550 | $55,749,999 | $55,776,551 | 23 | Jul 6, 2022 | sec.gov |
| Dec 4, 2017 | New notice | $20,000,000 | $20,000,000 | 1 | Nov 20, 2017 | sec.gov | |
| May 8, 2017 | New notice | $50,539,341 | $45,539,314 | $5,000,027 | 18 | Apr 24, 2017 | sec.gov |
| Apr 27, 2016 | New notice | $15,007,220 | $15,007,220 | 10 | Apr 12, 2016 | sec.gov | |
| Dec 30, 2015 | New notice | $4,000,000 | $4,000,000 | 8 | Dec 16, 2015 | sec.gov | |
| Jun 5, 2015 | Amendment | $20,000,000 | $20,000,000 | 8 | Jul 30, 2013 | sec.gov | |
| Aug 11, 2014 | Amendment | $20,000,000 | $12,999,999 | $7,000,001 | 8 | Jul 30, 2013 | sec.gov |
| Aug 13, 2013 | New notice | $20,000,000 | $12,999,999 | $7,000,001 | 8 | Jul 30, 2013 | sec.gov |
| Feb 7, 2011 | New notice | $9,600,002 | $9,600,002 | 7 | Jan 31, 2011 | sec.gov | |
| Sep 24, 2010 | New notice | $400,002 | $400,002 | 7 | Sep 15, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Mary DiBiase | Executive Officer | |
| Murray W. Stewart | Director | |
| Christophe Arbet-Engels | Executive Officer | |
| David Kirske | Executive Officer | |
| Michael S. Wyzga | Director | |
| John Volpone | Executive Officer | |
| Mark Baldry | Executive Officer | |
| Francoise J. De Craecker | Director | |
| Gary J. Bridger | Director | |
| Adam Craig | Executive Officer, Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Aug 25, 2025 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what X4 Pharmaceuticals, Inc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.